III. Identification of novel CXCR3 chemokine receptor antagonists with a pyrazinyl-piperazinyl-piperidine scaffold was written by Kim, Seong Heon;Anilkumar, Gopinadhan N.;Zawacki, Lisa Guise;Zeng, Qingbei;Yang, De-Yi;Shao, Yuefei;Dong, Guizhen;Xu, Xiaolian;Yu, Wensheng;Jiang, Yueheng;Jenh, Chung-Her;Hall, James W. III;Carroll, Carolyn DiIanni;Hobbs, Doug W.;Baldwin, John J.;McGuinness, Brian F.;Rosenblum, Stuart B.;Kozlowski, Joseph A.;Shankar, Bandarpalle B.;Shih, Neng-Yang. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2011.Recommanded Product: (S)-2-Ethylpiperazine This article mentions the following:
The SAR of a novel pyrazinyl-piperazinyl-piperidine scaffold with CXCR3 receptor antagonist activity was explored. Optimization of the DMPK profile and reduction of hERG inhibition is described. One compound with single-digit CXCR3 affinity and good rat PK and hERG profiles has been identified as a lead for further study. In the experiment, the researchers used many compounds, for example, (S)-2-Ethylpiperazine (cas: 207284-20-6Recommanded Product: (S)-2-Ethylpiperazine).
(S)-2-Ethylpiperazine (cas: 207284-20-6) belongs to piperazine derivatives. Piperazine causes primary dermal irritation and skin burns at high concentrations. Piperazine also causes eye irritation in humans. Piperazine and its salts did not induce point mutations in a bacterial test. A series of mutagenicity studies in cells, both in vitro and in vivo, has been completed and showed no evidence of mutagenic effect.Recommanded Product: (S)-2-Ethylpiperazine
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics